Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

  • Received : 2015.02.07
  • Accepted : 2015.04.02
  • Published : 2015.06.01
⟨ Previous Next ⟩

Abstract

The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.

Keywords

References

  1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926 https://doi.org/10.1136/bmj.39489.470347.AD
  2. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ; GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-998 https://doi.org/10.1136/bmj.39490.551019.BE
  3. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ 2008;336:1049-1051 https://doi.org/10.1136/bmj.39493.646875.AE
  4. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-1110 https://doi.org/10.1136/bmj.39500.677199.AE
  5. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ 2010;182:1045-1052 https://doi.org/10.1503/cmaj.091714
  6. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ 2010;182:E472-E478 https://doi.org/10.1503/cmaj.091716
  7. National Cancer Control Institute. Cancer facts and figures 2011 [Internet]. Goyang: National Cancer Center, 2011 [cited 2014 Mar 26]. Available from: http://ncc.re.kr/english/infor/kccr.jsp
  8. National Cancer Control Institute. Cancer facts and figures 2010 [Internet]. Goyang: National Cancer Center, 2011 [cited 2014 Mar 26]. Available from: http://ncc.re.kr/manage/manage03_033_list.jsp
  9. Korean Association for the Study of the Liver. White paper on liver diseases in Korea. Seoul: Korean Association for the Study of the Liver, 2013
  10. Korean Statistical Information Service. Statistical database 2012 [Internet]. Daejeon: Statistics Korea, c2014 [cited 2014 Mar 26]. Available from: http://kosis.kr/eng/statisticsList/statisticsList_01List.jsp?vwcd=MT_ETITLE&parentId=A
  11. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67 https://doi.org/10.1002/hep.510290145
  12. The Korean Liver Cancer Study Group; Korean Central Cancer Registry. A nationwide random sample study 2010 [Internet]. Seoul: The Korean Liver Cancer Study Group, 2010 [cited 2014 Mar 26]. Available from: http://www.klcsg.or.kr/index.asp
  13. Kwak HW, Park JW, Nam BH, Yu A, Woo SM, Kim TH, et al. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2014;29:820-829 https://doi.org/10.1111/jgh.12470
  14. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255 https://doi.org/10.1016/S0140-6736(11)61347-0
  15. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127 https://doi.org/10.1056/NEJMra1001683
  16. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-471 https://doi.org/10.1002/hep.24397
  17. Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008;371:367-368 https://doi.org/10.1016/S0140-6736(08)60181-6
  18. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-945.e4 https://doi.org/10.1016/j.cgh.2007.02.039
  19. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310 https://doi.org/10.1002/hep.21176
  20. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-1355 https://doi.org/10.1093/jnci/djp288
  21. WHO Publication. Hepatitis B vaccines: WHO position paper--recommendations. Vaccine 2010;28:589-590 https://doi.org/10.1016/j.vaccine.2009.10.110
  22. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162 https://doi.org/10.3350/cmh.2012.18.2.109
  23. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427 https://doi.org/10.1056/NEJM199605303342202
  24. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531 https://doi.org/10.1056/NEJMoa033364
  25. Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3:e003265 https://doi.org/10.1136/bmjopen-2013-003265
  26. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107
  27. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferonalpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055 https://doi.org/10.1016/S0140-6736(95)91739-X
  28. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-1875 https://doi.org/10.1002/hep.510290616
  29. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-288. e1 https://doi.org/10.1016/j.cgh.2009.11.018
  30. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-849 https://doi.org/10.1053/j.gastro.2010.11.050
  31. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441 https://doi.org/10.1056/NEJMoa0707615
  32. Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990-1999 https://doi.org/10.1053/j.gastro.2011.03.010
  33. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013;31:3647-3655 https://doi.org/10.1200/JCO.2012.48.5896
  34. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Longterm results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012;255:8-17 https://doi.org/10.1097/SLA.0b013e3182363ff9
  35. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104-1112 https://doi.org/10.1111/j.1365-2036.2011.04634.x
  36. Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010;16:2931-2942 https://doi.org/10.3748/wjg.v16.i23.2931
  37. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306 https://doi.org/10.7326/0003-4819-138-4-200302180-00008
  38. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554 https://doi.org/10.1002/hep.21415
  39. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42:218-224
  40. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468 https://doi.org/10.1053/j.gastro.2003.10.065
  41. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated metaanalysis. Clin Gastroenterol Hepatol 2013;11:1413-1421.e1 https://doi.org/10.1016/j.cgh.2013.04.039
  42. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47 https://doi.org/10.1111/j.1365-2036.2009.04014.x
  43. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-1424 https://doi.org/10.1016/j.cgh.2008.08.005
  44. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422
  45. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364 https://doi.org/10.1159/000327577
  46. Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, et al. Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma: using ROC curve. Korean J Hepatol 2006;12:404-411
  47. Yoon YJ, Han KH, Kim C, Chon CY, Moon YM, Han CH, et al. Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma. Korean J Hepatol 2002;8:465-471
  48. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474 https://doi.org/10.1007/s12072-010-9165-7
  49. Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014;59:986-995 https://doi.org/10.1002/hep.26739
  50. Krinsky GA, Lee VS, Theise ND, Weinreb JC, Morgan GR, Diflo T, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002;8:1156-1164 https://doi.org/10.1053/jlts.2002.35670
  51. Zacherl J, Pokieser P, Wrba F, Scheuba C, Prokesch R, Zacherl M, et al. Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann Surg 2002;235:528-532 https://doi.org/10.1097/00000658-200204000-00011
  52. Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW, et al. Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology 2008;51 Suppl 1:52-60 https://doi.org/10.1159/000122598
  53. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51 https://doi.org/10.1111/j.1872-034X.2007.00216.x
  54. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-523 https://doi.org/10.1111/j.1572-0241.2006.00467.x
  55. Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S178-S192 https://doi.org/10.1111/j.1872-034X.2007.00183.x
  56. Lee MH, Kim SH, Park MJ, Park CK, Rhim H. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-bvalue diffusion-weighted imaging to distinguish welldifferentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol 2011;197:W868-W875 https://doi.org/10.2214/AJR.10.6237
  57. Kim JE, Kim SH, Lee SJ, Rhim H. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acidenhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol 2011;196:W758-W765 https://doi.org/10.2214/AJR.10.4394
  58. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943 https://doi.org/10.1016/j.jhep.2011.12.001
  59. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-1921 https://doi.org/10.2967/jnumed.108.055087
  60. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-142 https://doi.org/10.1055/s-2005-871193
  61. Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 2005;3(10 Suppl 2):S136-S140 https://doi.org/10.1016/S1542-3565(05)00707-X
  62. Korean Liver Cancer Study Group; National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423 https://doi.org/10.3350/kjhep.2009.15.3.391
  63. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30:17-25 https://doi.org/10.1055/s-0030-1247129
  64. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104
  65. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma: what is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437-447 https://doi.org/10.1016/j.ctrv.2007.04.001
  66. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-1596 https://doi.org/10.1136/gut.2008.149062
  67. Bae SY, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, et al. Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area. Clin Mol Hepatol 2012;18:185-194 https://doi.org/10.3350/cmh.2012.18.2.185
  68. Pierce DA, Preston DL. Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 2000;154:178-186 https://doi.org/10.1667/0033-7587(2000)154[0178:RRCRAL]2.0.CO;2
  69. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003;160:381-407 https://doi.org/10.1667/RR3049
  70. Sont WN, Zielinski JM, Ashmore JP, Jiang H, Krewski D, Fair ME, et al. First analysis of cancer incidence and occupational radiation exposure based on the National Dose Registry of Canada. Am J Epidemiol 2001;153:309-318 https://doi.org/10.1093/aje/153.4.309
  71. Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C, et al. Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ 2005;331:77 https://doi.org/10.1136/bmj.38499.599861.E0
  72. Gilbert ES. Invited commentary: studies of workers exposed to low doses of radiation. Am J Epidemiol 2001;153:319-322 https://doi.org/10.1093/aje/153.4.319
  73. Upton AC; National Coluncil on Radiation Protection and Measurements Scientific Committee 1-6. The state of the art in the 1990's: NCRP report No. 136 on the scientific bases for linearity in the dose-response relationship for ionizing radiation. Health Phys 2003;85:15-22 https://doi.org/10.1097/00004032-200307000-00005
  74. Huda W, Ogden KM, Khorasani MR. Converting dose-length product to effective dose at CT. Radiology 2008;248:995-1003 https://doi.org/10.1148/radiol.2483071964
  75. National Research Council, Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Health risks from exposure to low levels of ionizing radiation: BEIR VII, phase 2. Washington, DC: National Academies Press, 2006
  76. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37:1-332
  77. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231 https://doi.org/10.1016/j.jhep.2005.10.013
  78. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
  79. Meier V, Ramadori G. Clinical staging of hepatocellular carcinoma. Dig Dis 2009;27:131-141 https://doi.org/10.1159/000218345
  80. Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002;24:395-403 https://doi.org/10.1016/S1386-6346(02)00144-4
  81. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 3rd English ed. Tokyo: Kanehara, 2010
  82. Koh DW, Park JW, Oh SE, Kim JH, Choi JI, Kim SH, et al. Characteristics of the patients with extrahepatic metastases developed in modified UICC T1-T2 stage hepatocellular carcinoma. Paper presented at: Asian Pacific Association for the Study of the Liver Annual Meeting; 2007; Kyoto, Japan. Abtract P-0573
  83. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 https://doi.org/10.1002/hep.20933
  84. Lang H, Sotiropoulos GC, Domland M, Fruhauf NR, Paul A, Husing J, et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005;92:198-202 https://doi.org/10.1002/bjs.4763
  85. Capussotti L, Muratore A, Massucco P, Ferrero A, Polastri R, Bouzari H. Major liver resections for hepatocellular carcinoma on cirrhosis: early and long-term outcomes. Liver Transpl 2004;10(2 Suppl 1):S64-S68 https://doi.org/10.1002/lt.20035
  86. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63-70 https://doi.org/10.1097/00000658-200107000-00010
  87. Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, et al. Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg 2013;17:66-77 https://doi.org/10.1007/s11605-012-2005-4
  88. Kim JH, Choi DW, Kim SB. Saftey and long-term outcome following major hepatectomy for hepatocellular carcinoma combined with compensated liver cirrhosis. J Korean Surg Soc 2006;70:444-450
  89. Huang J, Zhang Y, Peng Z, Gao H, Xu L, Jiao LR, et al. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol 2013;139:1709-1719 https://doi.org/10.1007/s00432-013-1497-y
  90. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West Study Group. Ann Surg 2013;257:929-937 https://doi.org/10.1097/SLA.0b013e31828329b8
  91. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649 https://doi.org/10.1002/bjs.1800600817
  92. Farges O, Malassagne B, Flejou JF, Balzan S, Sauvanet A, Belghiti J. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg 1999;229:210-215 https://doi.org/10.1097/00000658-199902000-00008
  93. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38-46 https://doi.org/10.1016/S1072-7515(00)00261-1
  94. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004;10(2 Suppl 1):S46-S52 https://doi.org/10.1002/lt.20044
  95. Fan ST, Lai EC, Lo CM, Ng IO, Wong J. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995;130:198-203 https://doi.org/10.1001/archsurg.1995.01430020088017
  96. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440 https://doi.org/10.1002/hep.510300629
  97. An M, Park JW, Shin JA, Choi JI, Kim TH, Kim SH, et al. The adverse effect of indirectly diagnosed portal hypertension on the complications and prognosis after hepatic resection of hepatocellular carcinoma. Korean J Hepatol 2006;12:553-561
  98. Choi GH, Park JY, Hwang HK, Kim DH, Kang CM, Choi JS, et al. Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. Liver Int 2011;31:485-493 https://doi.org/10.1111/j.1478-3231.2010.02436.x
  99. Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992-999 https://doi.org/10.1007/s00268-005-0524-9
  100. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-1916 https://doi.org/10.1053/j.gastro.2008.02.091
  101. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009;250:922-928 https://doi.org/10.1097/SLA.0b013e3181b977a5
  102. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg 2012;29:6-17 https://doi.org/10.1159/000335713
  103. Kim SU, Ahn SH, Park JY, Kim do Y, Chon CY, Choi JS, et al. Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan((R))) before curative resection of hepatocellular carcinoma: a pilot study. Hepatol Int 2008;2:471-477 https://doi.org/10.1007/s12072-008-9091-0
  104. Wong JS, Wong GL, Chan AW, Wong VW, Cheung YS, Chong CN, et al. Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. Ann Surg 2013;257:922-928 https://doi.org/10.1097/SLA.0b013e318269d2ec
  105. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706-712 https://doi.org/10.1097/SLA.0b013e3182724ce8
  106. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18:457-467 https://doi.org/10.1007/s00330-007-0716-9
  107. Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192:1675-1681 https://doi.org/10.2214/AJR.08.1262
  108. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2012;81:2417-2422 https://doi.org/10.1016/j.ejrad.2011.08.004
  109. Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, Reich D, et al. A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg 2005;241:622-628 https://doi.org/10.1097/01.sla.0000157267.27356.80
  110. Kim IS, Lim YS, Yoon HK, Sung KB, Jang MK, Choi WB, et al. The effect of preoperative transarterial chemoembolization on the patient's outcome in resectable hepatocellular carcinoma. Korean J Med 2005;69:614-621
  111. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995;82:122-126 https://doi.org/10.1002/bjs.1800820141
  112. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217
  113. Tanaka H, Hirohashi K, Kubo S, Shuto T, Higaki I, Kinoshita H. Preoperative portal vein embolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function. Br J Surg 2000;87:879-882 https://doi.org/10.1046/j.1365-2168.2000.01438.x
  114. Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, et al. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One 2013;8:e64261 https://doi.org/10.1371/journal.pone.0064261
  115. Tsujita E, Taketomi A, Kitagawa D, Itoh S, Harimoto N, Gion T, et al. Selective hepatic vascular exclusion for the hepatic resection of HCC. Hepatogastroenterology 2007;54:527-530
  116. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143:469-475 https://doi.org/10.1016/j.surg.2007.12.003
  117. Tanaka K, Shimada H, Matsumoto C, Matsuo K, Nagano Y, Endo I, et al. Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery 2008;143:607-615 https://doi.org/10.1016/j.surg.2008.01.006
  118. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007;245:36-43 https://doi.org/10.1097/01.sla.0000231758.07868.71
  119. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000;231:544-551 https://doi.org/10.1097/00000658-200004000-00014
  120. Suh KS. Systematic hepatectomy for small hepatocellular carcinoma in Korea. J Hepatobiliary Pancreat Surg 2005;12:365-370 https://doi.org/10.1007/s00534-005-1002-3
  121. Wakai T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K, et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007;14:1356-1365 https://doi.org/10.1245/s10434-006-9318-z
  122. Yin Z, Fan X, Ye H, Yin D, Wang J. Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol 2013;20:1203-1215 https://doi.org/10.1245/s10434-012-2705-8
  123. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2,804 patients. Ann Surg 2009;250:831-841 https://doi.org/10.1097/SLA.0b013e3181b0c4df
  124. Lai EC, Yang GP, Tang CN. Robot-assisted laparoscopic liver resection for hepatocellular carcinoma: short-term outcome. Am J Surg 2013;205:697-702 https://doi.org/10.1016/j.amjsurg.2012.08.015
  125. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536 https://doi.org/10.1200/JCO.20.6.1527
  126. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450-457 https://doi.org/10.1001/archsurg.140.5.450
  127. Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH, Ahn CS. Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg 2007;94:320-326 https://doi.org/10.1002/bjs.5622
  128. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-643 https://doi.org/10.7150/jca.7279
  129. Iakova P, Awad SS, Timchenko NA. Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 2003;113:495-506 https://doi.org/10.1016/S0092-8674(03)00318-0
  130. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007;204:854-862 https://doi.org/10.1016/j.jamcollsurg.2006.12.032
  131. Hai L, Yong-Hong P, Yong F, Ren-Feng L. One-stage liver resection for spontaneous rupture of hepatocellular carcinoma. World J Surg 2005;29:1316-1318 https://doi.org/10.1007/s00268-005-7626-2
  132. Bae JH, Hong SW, Heo TG, Lee H. Characteristics and prognosis after resection for ruptured hepatocellular carcinoma. Korean J HBP Surg 2006;10:37-41
  133. Buczkowski AK, Kim PT, Ho SG, Schaeffer DF, Lee SI, Owen DA, et al. Multidisciplinary management of ruptured hepatocellular carcinoma. J Gastrointest Surg 2006;10:379-386 https://doi.org/10.1016/j.gassur.2005.10.012
  134. Zhu Q, Li J, Yan JJ, Huang L, Wu MC, Yan YQ. Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol 2012;18:7302-7307 https://doi.org/10.3748/wjg.v18.i48.7302
  135. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403-410 https://doi.org/10.1016/j.surg.2004.12.012
  136. Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol 2013;20:3754-3760 https://doi.org/10.1245/s10434-013-3074-7
  137. Moon DB, Hwang S, Wang HJ, Yun SS, Kim KS, Lee YJ, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study. World J Surg 2013;37:443-451 https://doi.org/10.1007/s00268-012-1845-0
  138. Belghiti J, Guevara OA, Noun R, Saldinger PF, Kianmanesh R. Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 2001;193:109-111 https://doi.org/10.1016/S1072-7515(01)00909-7
  139. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006;244:194-203 https://doi.org/10.1097/01.sla.0000225095.18754.45
  140. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238:703-710 https://doi.org/10.1097/01.sla.0000094549.11754.e6
  141. Finkelstein SD, Marsh W, Demetris AJ, Swalsky PA, Sasatomi E, Bonham A, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003;37:871-879 https://doi.org/10.1053/jhep.2003.50134
  142. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207
  143. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol 2011;37:521-525 https://doi.org/10.1016/j.ejso.2011.03.137
  144. Li SH, Guo ZX, Xiao CZ, Wei W, Shi M, Chen ZY, et al. Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev 2013;14:4759-4763 https://doi.org/10.7314/APJCP.2013.14.8.4759
  145. Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009;249:799-805 https://doi.org/10.1097/SLA.0b013e3181a38eb5
  146. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243:229-235 https://doi.org/10.1097/01.sla.0000197706.21803.a1
  147. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010;102:462-468 https://doi.org/10.1002/jso.21631
  148. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-897 https://doi.org/10.1016/j.jhep.2009.07.009
  149. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72 Suppl 1:52-57 https://doi.org/10.1159/000111707
  150. Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, et al. Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann Surg Oncol 2008;15:618-629 https://doi.org/10.1245/s10434-007-9671-6
  151. Nagano Y, Shimada H, Ueda M, Matsuo K, Tanaka K, Endo I, et al. Efficacy of repeat hepatic resection for recurrent hepatocellular carcinomas. ANZ J Surg 2009;79:729-733 https://doi.org/10.1111/j.1445-2197.2009.05059.x
  152. Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 2012;19:2515-2525 https://doi.org/10.1245/s10434-012-2269-7
  153. Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl 2013;19:411-419 https://doi.org/10.1002/lt.23605
  154. Chan DL, Alzahrani NA, Morris DL, Chua TC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:31-41 https://doi.org/10.1111/jgh.12399
  155. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703 https://doi.org/10.1148/radiology.216.3.r00se24698
  156. Kuo SW, Chang YL, Huang PM, Hsu HH, Chen JS, Lee JM, et al. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2007;14:992-997 https://doi.org/10.1245/s10434-006-9217-3
  157. Nakagawa T, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, et al. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg 2006;131:1248-1254 https://doi.org/10.1016/j.jtcvs.2006.02.009
  158. Koneru B, Cassavilla A, Bowman J, Iwatsuki S, Starzl TE. Liver transplantation for malignant tumors. Gastroenterol Clin North Am 1988;17:177-193
  159. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221-228 https://doi.org/10.1097/00000658-199109000-00005
  160. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151 https://doi.org/10.1097/00000658-199308000-00005
  161. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311-322 https://doi.org/10.1055/s-2007-1007120
  162. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699 https://doi.org/10.1056/NEJM199603143341104
  163. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17 Suppl 2:S44-S57 https://doi.org/10.1002/lt.22365
  164. European Liver Transplant Registry (ELTR) [Internet]. Villejuif Cedex: European Liver Transplant Registry, 2014 [cited 2014 Feb 18]. Available from: http://www.eltr.org/
  165. Organ Procurement and Transplantation Network (OPTN) [Internet]. Richmond: Organ Procurement and Transplantation Network, 2014 [cited 2014 Feb 18]. Available from: http://optn.transplant.hrsa.gov/
  166. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 2011;17 Suppl 2:S58-S66 https://doi.org/10.1002/lt.22336
  167. Sugimachi K, Shirabe K, Taketomi A, Soejima Y, Iguchi T, Takeishi K, et al. Prognostic significance of preoperative imaging in recipients of living donor liver transplantation for hepatocellular carcinoma. Transplantation 2011;91:570-574 https://doi.org/10.1097/TP.0b013e318208134e
  168. Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-S43
  169. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-1660 https://doi.org/10.1002/lt.20861
  170. Kornberg A, Freesmeyer M, Barthel E, Jandt K, Katenkamp K, Steenbeck J, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592-600 https://doi.org/10.1111/j.1600-6143.2008.02516.x
  171. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-e22 https://doi.org/10.1016/S1470-2045(11)70175-9
  172. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851-858 https://doi.org/10.1053/jlts.2002.35927
  173. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278 https://doi.org/10.1002/lt.21999
  174. Korean Network for Organ Sharing (KONOS) [Internet]. Seoul: Korean Network for Organ Sharing, 2014 [cited 2014 Mar 18]. Available from: http://www.konos.go.kr/
  175. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-1272 https://doi.org/10.1002/lt.20549
  176. Kim MS. Comparison between Status with CTP score and MELD score in allocation of deceased donor liver: Korean national-based survey. Paper presented at: 2013 Congress of Asian Society of Transplantation; 2013 Kyoto, Japan
  177. Kim MS. Research for modification of emergency status in deceased donor liver allocation: development of revised MELD score system. Cheongju: Korea Centers for Disease Control and Prevention, 2014
  178. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-539 https://doi.org/10.1097/00000658-200204000-00012
  179. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 Suppl 1:S20-S37
  180. Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S6-S13 https://doi.org/10.1002/lt.22423
  181. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-1351 https://doi.org/10.1053/j.gastro.2008.02.013
  182. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839-846 https://doi.org/10.1111/j.1600-6143.2007.02138.x
  183. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403 https://doi.org/10.1053/jhep.2001.24563
  184. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43 https://doi.org/10.1016/S1470-2045(08)70284-5
  185. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010;10:129-137 https://doi.org/10.1111/j.1600-6143.2009.02750.x
  186. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008;14:1107-1115 https://doi.org/10.1002/lt.21484
  187. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909 https://doi.org/10.1097/01.sla.0000143301.56154.95
  188. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-128 https://doi.org/10.1136/gut.50.1.123
  189. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883 https://doi.org/10.1053/jlts.2002.34923
  190. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827 https://doi.org/10.1002/hep.22412
  191. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767-775 https://doi.org/10.1002/lt.20418
  192. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006;12:665-673 https://doi.org/10.1002/lt.20636
  193. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidencebased analysis. Am J Transplant 2006;6:2644-2650 https://doi.org/10.1111/j.1600-6143.2006.01509.x
  194. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009;15:859-868 https://doi.org/10.1002/lt.21778
  195. Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011;17:1344-1354 https://doi.org/10.1002/lt.22397
  196. De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009;9:1158-1168 https://doi.org/10.1111/j.1600-6143.2009.02576.x
  197. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008;8(4 Pt 2):958-976 https://doi.org/10.1111/j.1600-6143.2008.02174.x
  198. O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18:949-954 https://doi.org/10.1002/lt.23439
  199. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011;117:3053-3059 https://doi.org/10.1002/cncr.25809
  200. Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 2012;83:895-900 https://doi.org/10.1016/j.ijrobp.2011.08.032
  201. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8:2547-2557 https://doi.org/10.1111/j.1600-6143.2008.02409.x
  202. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617-625
  203. Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-1514 https://doi.org/10.1002/lt.20526
  204. Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int 2010;23:712-722 https://doi.org/10.1111/j.1432-2277.2010.01111.x
  205. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-1928 https://doi.org/10.1111/j.1600-6143.2009.02695.x
  206. Korean Organ Donation Agency (KODA) [Internet]. Seoul: Korean Organ Donation Agency; 2014 [cited 2014 May 12]. Available from: http://www.koda1458.kr/
  207. Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 2010;17:443-448 https://doi.org/10.1007/s00534-009-0241-0
  208. Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and metaanalysis. Clin Transplant 2013;27:140-147 https://doi.org/10.1111/ctr.12031
  209. Kulik LM, Fisher RA, Rodrigo DR, Brown RS Jr, Freise CE, Shaked A, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012;12:2997-3007 https://doi.org/10.1111/j.1600-6143.2012.04272.x
  210. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S277-S282 https://doi.org/10.1053/j.gastro.2004.09.042
  211. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and costeffectiveness perspective. Hepatology 2001;33:1073-1079 https://doi.org/10.1053/jhep.2001.23311
  212. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one largevolume center. Liver Transpl 2008;14:935-945 https://doi.org/10.1002/lt.21445
  213. Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol 2013;19:4737-4744 https://doi.org/10.3748/wjg.v19.i29.4737
  214. Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007;25:329-333 https://doi.org/10.1159/000106913
  215. Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007;25:313-319 https://doi.org/10.1159/000106911
  216. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007;25:310-312 https://doi.org/10.1159/000106910
  217. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007;13:1637-1644 https://doi.org/10.1002/lt.21281
  218. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-537 https://doi.org/10.1097/TP.0b013e3181943bee
  219. Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007;13(11 Suppl 2):S48-S54 https://doi.org/10.1002/lt.21334
  220. Siegler M, Simmerling MC, Siegler JH, Cronin DC 2nd. Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT). Liver Transpl 2006;12:358-360 https://doi.org/10.1002/lt.20670
  221. Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008;135:468-476 https://doi.org/10.1053/j.gastro.2008.04.018
  222. Brown RS Jr. Live donors in liver transplantation. Gastroenterology 2008;134:1802-1813 https://doi.org/10.1053/j.gastro.2008.02.092
  223. Yi NJ, Suh KS, Cho JY, Lee HW, Cho EH, Yang SH, et al. Threequarters of right liver donors experienced postoperative complications. Liver Transpl 2007;13:797-806 https://doi.org/10.1002/lt.21030
  224. Kim KH, Jung DH, Park KM, Lee YJ, Kim DY, Kim KM, et al. Comparison of open and laparoscopic live donor left lateral sectionectomy. Br J Surg 2011;98:1302-1308 https://doi.org/10.1002/bjs.7601
  225. Hwang S, Lee SG, Lee YJ, Sung KB, Park KM, Kim KH, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 2006;12:920-927 https://doi.org/10.1002/lt.20734
  226. Kim SJ, Na GH, Choi HJ, Yoo YK, Kim DG. Surgical outcome of right liver donors in living donor liver transplantation: single-center experience with 500 cases. J Gastrointest Surg 2012;16:1160-1170 https://doi.org/10.1007/s11605-012-1865-y
  227. Kim SH, Kim YK. Improving outcomes of living-donor right hepatectomy. Br J Surg 2013;100:528-534 https://doi.org/10.1002/bjs.9022
  228. Shin M, Song S, Kim JM, Kwon CH, Kim SJ, Lee SK, et al. Donor morbidity including biliary complications in livingdonor liver transplantation: single-center analysis of 827 cases. Transplantation 2012;93:942-948 https://doi.org/10.1097/TP.0b013e31824ad5de
  229. Chan SC, Chan AC, Sharr WW, Chok KS, Cheung TT, Fan ST, et al. Perpetuating proficiency in donor right hepatectomy for living donor liver transplantation. Asian J Surg 2014;37:65-72 https://doi.org/10.1016/j.asjsur.2013.09.001
  230. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-382 https://doi.org/10.1097/00000658-200203000-00009
  231. Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012;55:132-140 https://doi.org/10.1002/hep.24680
  232. Sapisochin G, Castells L, Dopazo C, Bilbao I, Minguez B, Lazaro JL, et al. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol 2013;20:1194-1202 https://doi.org/10.1245/s10434-012-2655-1
  233. Cucchetti A, Vitale A, Del Gaudio M, Ravaioli M, Ercolani G, Cescon M, et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010;10:619-627 https://doi.org/10.1111/j.1600-6143.2009.02984.x
  234. Hu Z, Wang W, Li Z, Ye S, Zheng SS. Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012;18:1316-1323 https://doi.org/10.1002/lt.23521
  235. Liu F, Wei Y, Wang W, Chen K, Yan L, Wen T, et al. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. PLoS One 2012;7:e48932 https://doi.org/10.1371/journal.pone.0048932
  236. Moon JI, Kwon CH, Joh JW, Choi GS, Jung GO, Kim JM, et al. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival. Transplant Proc 2012;44:487-493 https://doi.org/10.1016/j.transproceed.2011.11.009
  237. Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007;13:741-746 https://doi.org/10.1002/lt.21157
  238. Kim BW, Park YK, Kim YB, Wang HJ, Kim MW. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. Transplant Proc 2008;40:3558-3561 https://doi.org/10.1016/j.transproceed.2008.03.175
  239. Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, et al. Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. Surgery 2012;151:55-60 https://doi.org/10.1016/j.surg.2011.06.032
  240. Wu L, Hu A, Tam N, Zhang J, Lin M, Guo Z, et al. Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. PLoS One 2012;7:e41820 https://doi.org/10.1371/journal.pone.0041820
  241. Li HY, Wei YG, Yan LN, Li B. Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2012;18:2415-2422 https://doi.org/10.3748/wjg.v18.i19.2415
  242. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005;43:584-589 https://doi.org/10.1016/j.jhep.2005.07.019
  243. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008;14:633-638 https://doi.org/10.1002/lt.21420
  244. Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83:1162-1168 https://doi.org/10.1097/01.tp.0000262607.95372.e0
  245. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:62-69 https://doi.org/10.1002/lt.22441
  246. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-1360 https://doi.org/10.1002/hep.20465
  247. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-89
  248. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-967 https://doi.org/10.1148/radiol.2343040350
  249. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-1723 https://doi.org/10.1053/j.gastro.2004.09.003
  250. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-130 https://doi.org/10.1053/j.gastro.2005.04.009
  251. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240 https://doi.org/10.1148/radiol.2281020718
  252. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Tenyear outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013;58:89-97 https://doi.org/10.1016/j.jhep.2012.09.020
  253. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-577 https://doi.org/10.1038/ajg.2011.425
  254. de Baere T, Risse O, Kuoch V, Dromain C, Sengel C, Smayra T, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003;181:695-700 https://doi.org/10.2214/ajr.181.3.1810695
  255. Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics 2003;23:123-134 https://doi.org/10.1148/rg.231025054
  256. Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009;19:2630-2640 https://doi.org/10.1007/s00330-009-1463-x
  257. Lee MW, Rhim H, Cha DI, Kim YJ, Lim HK. Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1-3 cm): value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol 2013;24:958-965 https://doi.org/10.1016/j.jvir.2013.04.007
  258. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78 Suppl 1:40-45
  259. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-1156 https://doi.org/10.1136/gut.2004.045203
  260. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008;43:727-735 https://doi.org/10.1080/00365520701885481
  261. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-459 https://doi.org/10.1002/hep.22648
  262. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-328 https://doi.org/10.1097/01.sla.0000201480.65519.b8
  263. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794-802 https://doi.org/10.1016/j.jhep.2012.05.007
  264. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903-912 https://doi.org/10.1097/SLA.0b013e3181efc656
  265. Qi X, Tang Y, An D, Bai M, Shi X, Wang J, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol 2014;48:450-457
  266. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010;51:1284-1290 https://doi.org/10.1002/hep.23466
  267. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009;252:905-913 https://doi.org/10.1148/radiol.2523081676
  268. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediatesized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116:5452-5460 https://doi.org/10.1002/cncr.25314
  269. Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2013;25:187-194 https://doi.org/10.1097/MEG.0b013e32835a0a07
  270. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013;19:3872-3882 https://doi.org/10.3748/wjg.v19.i24.3872
  271. Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery 2012;151:700-709 https://doi.org/10.1016/j.surg.2011.12.015
  272. Liang HH, Chen MS, Peng ZW, Zhang YJ, Zhang YQ, Li JQ, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol 2008;15:3484-3493 https://doi.org/10.1245/s10434-008-0076-y
  273. Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Fan ST, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg 2012;36:151-156 https://doi.org/10.1007/s00268-011-1323-0
  274. Cha DI, Lee MW, Rhim H, Choi D, Kim YS, Lim HK. Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations. Korean J Radiol 2013;14:240-247 https://doi.org/10.3348/kjr.2013.14.2.240
  275. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996;77:1792-1796 https://doi.org/10.1002/(SICI)1097-0142(19960501)77:9<1792::AID-CNCR6>3.0.CO;2-E
  276. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-357 https://doi.org/10.1002/hep.1840160212
  277. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: a study on 207 patients. Cancer 1992;69:925-929 https://doi.org/10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO;2-G
  278. Daniele B, De Sio I, Izzo F, Capuano G, Andreana A, Mazzanti R, et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol 2003;36:63-67 https://doi.org/10.1097/00004836-200301000-00017
  279. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005;242:36-42 https://doi.org/10.1097/01.sla.0000167925.90380.fe
  280. Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005;236:132-139 https://doi.org/10.1148/radiol.2361031249
  281. Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010;21(8 Suppl):S192-S203 https://doi.org/10.1016/j.jvir.2010.04.007
  282. Sotiropoulos GC, Lang H, Frilling A, Molmenti EP, Paul A, Nadalin S, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology 2006;53:322-329
  283. Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the italian society of interventional radiology. Cardiovasc Intervent Radiol 2014;37:438-444 https://doi.org/10.1007/s00270-013-0656-5
  284. Park JW, Sherman M, Colombo M, Roberts LR, Schwartz ME, Degos F, et al. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: first characterization of the full study population. J Clin Oncol 2012;30 Suppl:abstr 4033
  285. Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. AJR Am J Roentgenol 2012;198:692-699 https://doi.org/10.2214/AJR.11.7066
  286. Satake M, Uchida H, Arai Y, Anai H, Sakaguchi H, Nagata T, et al. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE Study Group of Japan. Cardiovasc Intervent Radiol 2008;31:756-761 https://doi.org/10.1007/s00270-007-9255-7
  287. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009;20(7 Suppl):S425-S434 https://doi.org/10.1016/j.jvir.2009.04.021
  288. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S188 https://doi.org/10.1053/j.gastro.2004.09.032
  289. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83 https://doi.org/10.1148/radiology.188.1.8390073
  290. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739 https://doi.org/10.1016/S0140-6736(02)08649-X
  291. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171 https://doi.org/10.1053/jhep.2002.33156
  292. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469 https://doi.org/10.1053/j.gastro.2006.05.021
  293. Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, et al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol 2013;24:490-500 https://doi.org/10.1016/j.jvir.2013.01.003
  294. Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol 2009;20:209-216 https://doi.org/10.1016/j.jvir.2008.10.021
  295. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747-1752 https://doi.org/10.1002/cncr.10407
  296. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007;18:365-376 https://doi.org/10.1016/j.jvir.2006.12.004
  297. Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-4465 https://doi.org/10.1200/JCO.2002.02.013
  298. Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol 2012;81:1173-1178 https://doi.org/10.1016/j.ejrad.2011.03.046
  299. Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014;271:909-918 https://doi.org/10.1148/radiol.13131760
  300. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258:627-634 https://doi.org/10.1148/radiol.10101058
  301. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653-1659 https://doi.org/10.1097/01.RVI.0000182185.47500.7A
  302. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997;79:2087-2094 https://doi.org/10.1002/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M
  303. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995;165:315-321 https://doi.org/10.2214/ajr.165.2.7618547
  304. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413-420 https://doi.org/10.1245/s10434-010-1321-8
  305. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52 https://doi.org/10.1007/s00270-009-9711-7
  306. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-481 https://doi.org/10.1016/j.jhep.2006.10.020
  307. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-1552 https://doi.org/10.1016/j.jvir.2011.07.002
  308. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads: implications for clinical practice and trial design. J Hepatol 2012;56:1330-1335 https://doi.org/10.1016/j.jhep.2012.01.008
  309. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicineluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012;35:1119-1128 https://doi.org/10.1007/s00270-012-0394-0
  310. Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, et al. Safety and efficacy of doxorubicin drugeluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013;24:307-315 https://doi.org/10.1016/j.jvir.2012.11.026
  311. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-1837 https://doi.org/10.1002/hep.26014
  312. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64 https://doi.org/10.1053/j.gastro.2009.09.006
  313. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-878 https://doi.org/10.1002/hep.24451
  314. Kim DY, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, et al. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. Epub 2013 Sep 21. http://dx.doi.org/10.1097/COC.0b013e3182a78dba
  315. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653-1663 https://doi.org/10.1002/cncr.21811
  316. Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-231 https://doi.org/10.1016/j.ijrobp.2006.08.015
  317. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-1378 https://doi.org/10.1016/j.ijrobp.2005.01.002
  318. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S94-S100 https://doi.org/10.1016/j.ijrobp.2009.06.092
  319. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-e453 https://doi.org/10.1016/j.ijrobp.2011.04.011
  320. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-1639 https://doi.org/10.1200/JCO.2012.44.1659
  321. Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:530-536 https://doi.org/10.1111/jgh.12087
  322. Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012;84:355-361 https://doi.org/10.1016/j.ijrobp.2011.11.058
  323. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-5431 https://doi.org/10.1002/cncr.27533
  324. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399-404 https://doi.org/10.3109/0284186X.2013.820342
  325. Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One 2013;8:e79854 https://doi.org/10.1371/journal.pone.0079854
  326. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009;74:831-836 https://doi.org/10.1016/j.ijrobp.2008.10.073
  327. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-1846 https://doi.org/10.1200/JCO.2005.00.620
  328. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011;117:4890-4904 https://doi.org/10.1002/cncr.26134
  329. Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009;115:5499-5506 https://doi.org/10.1002/cncr.24619
  330. Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, et al. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci 2013;28:213-219 https://doi.org/10.3346/jkms.2013.28.2.213
  331. Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, et al. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int 014;34:795-801 https://doi.org/10.1111/liv.12445
  332. Eun HS, Kim MJ, Kim HJ, Ko KH, Moon HS, Lee ES, et al. The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care. Korean J Hepatol 2011;17:189-198 https://doi.org/10.3350/kjhep.2011.17.3.189
  333. Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol 2009;44:492-502 https://doi.org/10.1007/s00535-009-0033-y
  334. Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426 https://doi.org/10.1002/cncr.21043
  335. Lo CH, Huang WY, Lee MS, Lin KT, Lin TP, Chang PY, et al. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. Eur J Gastroenterol Hepatol 2014;26:345-352 https://doi.org/10.1097/MEG.0000000000000032
  336. McIntosh A, Hagspiel KD, Al-Osaimi AM, Northup P, Caldwell S, Berg C, et al. Accelerated treatment using intensitymodulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 2009;115:5117-5125 https://doi.org/10.1002/cncr.24552
  337. Shirai S, Sato M, Suwa K, Kishi K, Shimono C, Sonomura T, et al. Feasibility and efficacy of single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma 8 cm or more with portal vein tumor thrombus in combination with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 2010;76:1037-1044 https://doi.org/10.1016/j.ijrobp.2009.03.023
  338. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, et al. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 2011;50:1191-1198 https://doi.org/10.3109/0284186X.2011.592147
  339. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 2009;185:782-788 https://doi.org/10.1007/s00066-009-2020-x
  340. Tanaka Y, Nakazawa T, Komori S, Hidaka H, Okuwaki Y, Takada J, et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. J Gastroenterol Hepatol 2014;29:352-357 https://doi.org/10.1111/jgh.12333
  341. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864 https://doi.org/10.1371/journal.pone.0063864
  342. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119 https://doi.org/10.1016/S0360-3016(03)00434-6
  343. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-2011 https://doi.org/10.1016/j.ijrobp.2011.03.019
  344. Yu JI, Park HC, Lim do H, Park W, Yoo BC, Paik SW, et al. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci 2011;26:1014-1022 https://doi.org/10.3346/jkms.2011.26.8.1014
  345. Hsu HC, Chen TY, Chiu KW, Huang EY, Leung SW, Huang YJ, et al. Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma. Br J Radiol 2007;80:38-42 https://doi.org/10.1259/bjr/55395102
  346. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-194 https://doi.org/10.1016/j.radonc.2008.11.002
  347. Oh D, Lim do H, Park HC, Paik SW, Koh KC, Lee JH, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol 2010;33:370-375 https://doi.org/10.1097/COC.0b013e3181b0c298
  348. Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, Kim JH, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009;29:147-152 https://doi.org/10.1111/j.1478-3231.2008.01873.x
  349. Tang QH, Li AJ, Yang GM, Lai EC, Zhou WP, Jiang ZH, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg 2013;37:1362-1370 https://doi.org/10.1007/s00268-013-1969-x
  350. Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and threedimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2010;78:180-187 https://doi.org/10.1016/j.ijrobp.2009.07.1730
  351. Yu JI, Park HC, Lim do H, Kim CJ, Oh D, Yoo BC, et al. Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci 2012;27:736-743 https://doi.org/10.3346/jkms.2012.27.7.736
  352. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003 https://doi.org/10.1002/cncr.23684
  353. Park MS, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH, et al. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol 2013;71:165-173 https://doi.org/10.1007/s00280-012-1993-9
  354. Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, et al. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol 2011;26:1123-1132 https://doi.org/10.1111/j.1440-1746.2011.06745.x
  355. Choi SB, Kim KS, Park YN, Choi JS, Lee WJ, Seong J, et al. The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci 2009;24:242-247 https://doi.org/10.3346/jkms.2009.24.2.242
  356. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006;29:568-575 https://doi.org/10.1097/01.coc.0000239147.60196.11
  357. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-1150 https://doi.org/10.1016/j.ijrobp.2004.08.028
  358. Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol 2003;21:249-255 https://doi.org/10.1002/ssu.10043
  359. Cheng SH, Lin YM, Chuang VP, Yang PS, Cheng JC, Huang AT, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025-1033 https://doi.org/10.1046/j.1440-1746.1999.01994.x
  360. Huang JF, Wang LY, Lin ZY, Chen SC, Hsieh MY, Chuang WL, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:190-195 https://doi.org/10.1046/j.1440-1746.2002.02677.x
  361. Jang JW, Kay CS, You CR, Kim CW, Bae SH, Choi JY, et al. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int J Radiat Oncol Biol Phys 2009;74:412-418 https://doi.org/10.1016/j.ijrobp.2008.08.034
  362. Park YJ, Lim do H, Paik SW, Koh KC, Lee JH, Choi MS, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 2006;41:1099-1106 https://doi.org/10.1007/s00535-006-1895-x
  363. Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, et al. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 2007;22:523-527 https://doi.org/10.1111/j.1440-1746.2006.04450.x
  364. Yoon SM, Kim JH, Choi EK, Ahn SD, Lee SW, Yi BY, et al. Radioresponse of hepatocellular carcinoma-treatment of lymph node metastasis. Cancer Res Treat 2004;36:79-84 https://doi.org/10.4143/crt.2004.36.1.79
  365. Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 2005;63:1067-1076 https://doi.org/10.1016/j.ijrobp.2005.03.058
  366. He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009;115:2710-2720 https://doi.org/10.1002/cncr.24300
  367. Kaizu T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998;93:2167-2171 https://doi.org/10.1111/j.1572-0241.1998.00614.x
  368. Murakami R, Baba Y, Furusawa M, Yokoyama T, Nishimura R, Uozumi H, et al. Short communication: the value of embolization therapy in painful osseous metastases from hepatocellular carcinomas: comparative study with radiation therapy. Br J Radiol 1996;69:1042-1044 https://doi.org/10.1259/0007-1285-69-827-1042
  369. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261-265 https://doi.org/10.1111/j.1478-3231.2005.01094.x
  370. Taki Y, Yamaoka Y, Takayasu T, Ino K, Shimahara Y, Mori K, et al. Bone metastases of hepatocellular carcinoma after liver resection. J Surg Oncol 1992;50:12-18 https://doi.org/10.1002/jso.2930500104
  371. Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009;91:307-313 https://doi.org/10.1007/s11060-008-9713-3
  372. Nakamura N, Igaki H, Yamashita H, Shiraishi K, Tago M, Sasano N, et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol 2007;37:38-43 https://doi.org/10.1093/jjco/hyl128
  373. Jiang W, Zeng ZC, Zhang JY, Fan J, Zeng MS, Zhou J. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clin Exp Metastasis 2012;29:197-205 https://doi.org/10.1007/s10585-011-9442-4
  374. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390 https://doi.org/10.1056/NEJMoa0708857
  375. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34 https://doi.org/10.1016/S1470-2045(08)70285-7
  376. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-4075 https://doi.org/10.1200/JCO.2012.45.8372
  377. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524 https://doi.org/10.1200/JCO.2012.48.4410
  378. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2013;31(Suppl 4):abstr 249
  379. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-165
  380. Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135:617-625 https://doi.org/10.1007/s00432-008-0496-x
  381. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011;68:1285-1290 https://doi.org/10.1007/s00280-011-1616-x
  382. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-617 https://doi.org/10.1111/ijcp.12352
  383. Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1756-1761 https://doi.org/10.1111/jgh.12310
  384. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol 2014;41 Suppl 2:S1-S16
  385. Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013;33:327-337 https://doi.org/10.1111/liv.12083
  386. Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-183 https://doi.org/10.1111/liv.12314
  387. Kim HY, Park JW, Joo J, Jung SJ, An S, Woo SM, et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1051-1056 https://doi.org/10.1111/j.1440-1746.2011.06963.x
  388. Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012;56:1336-1342 https://doi.org/10.1016/j.jhep.2012.01.006
  389. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Leberre MA, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012;30(Suppl 4):abstr LBA154
  390. Brandi G, de Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 2013;18:1256-1257 https://doi.org/10.1634/theoncologist.2013-0093
  391. Mir O, Coriat R, Boudou-Rouquette P, Ropert S, Durand JP, Cessot A, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pretreated with sorafenib. Med Oncol 2012;29:2793-2799 https://doi.org/10.1007/s12032-012-0208-x
  392. Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014;20:235-241 https://doi.org/10.3748/wjg.v20.i1.235
  393. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 $mg/m^2$) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984;68:487-491
  394. Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma: adriamycin versus quadruple chemotherapy. Cancer 1984;53:401-405 https://doi.org/10.1002/1097-0142(19840201)53:3<401::AID-CNCR2820530306>3.0.CO;2-L
  395. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma: experience with 109 patients. Cancer 1985;56:2751-2755 https://doi.org/10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O
  396. Tetef M, Doroshow J, Akman S, Coluzzi P, Leong L, Margolin K, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995;13:460-463 https://doi.org/10.3109/07357909509024907
  397. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000;89:750-756 https://doi.org/10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R
  398. Guan Z, Wang Y, Maoleekoonpairoj S, Chen Z, Kim WS, Ratanatharathorn V, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003;89:1865-1869 https://doi.org/10.1038/sj.bjc.6601369
  399. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol 2008;31:317-322 https://doi.org/10.1097/COC.0b013e318162f57d
  400. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578-586 https://doi.org/10.1002/cncr.20368
  401. Boige V, Taieb J, Hebbar M, Malka D, Debaere T, Hannoun L, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006;42:456-459 https://doi.org/10.1016/j.ejca.2005.09.034
  402. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691
  403. Barbare JC, Bouche O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009;45:1788-1797 https://doi.org/10.1016/j.ejca.2009.02.018
  404. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58 https://doi.org/10.1002/hep.510310111
  405. Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005;23:4338-4346 https://doi.org/10.1200/JCO.2005.05.470
  406. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538 https://doi.org/10.1093/jnci/dji315
  407. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501-3508 https://doi.org/10.1200/JCO.2012.44.5643
  408. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004;54:385-390 https://doi.org/10.1007/s00280-004-0837-7
  409. Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:459-467 https://doi.org/10.1007/s00280-008-0759-x
  410. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009;20:1402-1407 https://doi.org/10.1093/annonc/mdp010
  411. Keam B, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, et al. A phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with alpha fetoprotein as a predictive and prognostic marker. Mol Med Rep 2008;1:415-422
  412. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109:1384-1390 https://doi.org/10.1002/cncr.22532
  413. Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007;97:862-867 https://doi.org/10.1038/sj.bjc.6603956
  414. Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J 2008;14:123-127 https://doi.org/10.1097/PPO.0b013e31816a6058
  415. Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, et al. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014;44:1179-1185 https://doi.org/10.1111/hepr.12266
  416. Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2012;8:164-171 https://doi.org/10.1111/j.1743-7563.2012.01543.x
  417. Lim TY, Cheong JY, Cho SW, Sim SJ, Kim JS, Choi SJ, et al. Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis. Korean J Hepatol 2006;12:65-73
  418. Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, et al. A randomized comparative study of high-dose and lowdose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010;65:373-382 https://doi.org/10.1007/s00280-009-1126-2
  419. Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol 2004;15:835-841 https://doi.org/10.1097/01.RVI.0000128815.35555.0E
  420. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Hepatic arterial infusion chemotherapy using lowdose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010;78 Suppl 1:148-153 https://doi.org/10.1159/000315244
  421. Takaki-Hamabe S, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009;39:223-230 https://doi.org/10.1111/j.1872-034X.2008.00458.x
  422. Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011;81:281-290 https://doi.org/10.1159/000334439
  423. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009;137:850-855 https://doi.org/10.1053/j.gastro.2009.06.003
  424. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114-117 https://doi.org/10.1097/00000658-199108000-00004
  425. Chen X, Zhang B, Yin X, Ren Z, Qiu S, Zhou J. Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol 2013;139:773-781 https://doi.org/10.1007/s00432-012-1343-7
  426. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801 https://doi.org/10.1016/S0140-6736(98)06475-7
  427. Boucher E, Corbinais S, Rolland Y, Bourguet P, Guyader D, Boudjema K, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003;38:1237-1241 https://doi.org/10.1053/jhep.2003.50473
  428. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-807 https://doi.org/10.1016/S0140-6736(00)02654-4
  429. Shi HY, Wang SN, Wang SC, Chuang SC, Chen CM, Lee KT. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors. J Surg Oncol 2014;109:487-493 https://doi.org/10.1002/jso.23521
  430. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-1666 https://doi.org/10.1093/annonc/mdh430
  431. Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004;99:2369-2375 https://doi.org/10.1111/j.1572-0241.2004.40069.x
  432. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712 https://doi.org/10.1111/j.1365-2141.2006.06465.x
  433. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006;4:1076-1081 https://doi.org/10.1016/j.cgh.2006.05.027
  434. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-709 https://doi.org/10.1053/jhep.2002.35068
  435. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307 https://doi.org/10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
  436. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539 https://doi.org/10.1002/hep.21513
  437. Wu XY, Li X, Chen ZH, Wen JY, Lin Q, Xing YF, et al. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol 2013;34:909-918 https://doi.org/10.1007/s13277-012-0626-6
  438. Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006;35:467-469 https://doi.org/10.1016/j.jcv.2005.10.009
  439. Huang L, Li J, Yan J, Sun J, Zhang X, Wu M, et al. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepat 2013;20:336-342 https://doi.org/10.1111/jvh.12036
  440. Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg 2013;257:490-505 https://doi.org/10.1097/SLA.0b013e318262b218
  441. Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013;33:595-604 https://doi.org/10.1111/liv.12112
  442. Lao XM, Wang D, Shi M, Liu G, Li S, Guo R, et al. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res 2011;41:553-563 https://doi.org/10.1111/j.1872-034X.2011.00796.x
  443. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008;22:117-126 https://doi.org/10.1016/j.blre.2008.02.001
  444. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-240 https://doi.org/10.1002/hep.21024
  445. Park JW, Park KW, Cho SH, Park HS, Lee WJ, Lee DH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBVrelated hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005;100:2194-2200 https://doi.org/10.1111/j.1572-0241.2005.00232.x
  446. Jang JW, Kwon JH, You CR, Kim JD, Woo HY, Bae SH, et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther 2011;16:969-977 https://doi.org/10.3851/IMP1840
  447. Tamori A, Nishiguchi S, Tanaka M, Kurooka H, Fujimoto S, Nakamura K, et al. Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2003;26:77-80 https://doi.org/10.1016/S1386-6346(03)00002-0
  448. Nagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003;26:293-301 https://doi.org/10.1016/S1386-6346(03)00158-X
  449. Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, Shuto T, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 2001;233:139-145 https://doi.org/10.1097/00000658-200101000-00020
  450. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-819 https://doi.org/10.1016/j.ijrobp.2007.04.005
  451. Dan JQ, Zhang YJ, Huang JT, Chen MS, Gao HJ, Peng ZW, et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 2013;39:865-872 https://doi.org/10.1016/j.ejso.2013.03.020
  452. Yoshida H, Yoshida H, Goto E, Sato T, Ohki T, Masuzaki R, et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int 2008;2:89-94 https://doi.org/10.1007/s12072-007-9020-7
  453. Sung PS, Bae SH, Jang JW, Song do S, Kim HY, Yoo SH, et al. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean J Hepatol 2011;17:299-306 https://doi.org/10.3350/kjhep.2011.17.4.299
  454. Hong SH, Roh SY, Kim SY, Shin SW, Kim CS, Choi JH, et al. Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage 2011;41:93-103 https://doi.org/10.1016/j.jpainsymman.2010.03.025
  455. Kim JY, Jang WY, Hur MH, Lee KK, Do YR, Park KU, et al. Prevalence and management of pain by different age groups of Korean cancer patients. Am J Hosp Palliat Care 2013;30:393-398 https://doi.org/10.1177/1049909112452624
  456. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-1449 https://doi.org/10.1093/annonc/mdm056
  457. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742 https://doi.org/10.1056/NEJMoa1000678
  458. Carr BI, Pujol L. Pain at presentation and survival in hepatocellular carcinoma. J Pain 2010;11:988-993 https://doi.org/10.1016/j.jpain.2010.01.265
  459. Ryu E, Kim K, Cho MS, Kwon IG, Kim HS, Fu MR. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs 2010;33:3-10 https://doi.org/10.1097/NCC.0b013e3181b4367e
  460. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-1161 https://doi.org/10.1007/s00228-008-0553-z
  461. Radner H, Ramiro S, Buchbinder R, Landewe RB, van der Heijde D, Aletaha D. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Database Syst Rev 2012;1:CD008951
  462. World Health Organization. Cancer pain relief, 2nd ed. Geneva: World Health Organization, 1996
  463. Ministry of Health & Welfare. Cancer pain management guideline, 5th ed. Seoul: Ministry of Health & Welfare, 2012
  464. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: adult cancer pain, Vol. 1. Fort Washington: National Comprehensive Cancer Network, 2013
  465. Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, et al. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf 2008;31:261-270 https://doi.org/10.2165/00002018-200831030-00007
  466. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1364-1372 https://doi.org/10.1002/hep.20948
  467. U.S. Department of Health and Human Services; U.S. Food and Drug Administration. Drugs: acetaminophen information [Internet]. Silver Spring: U.S. Food and Drug Administration, 2013 [cited 2013 Jan 15]. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm165107.htm
  468. Mofredj A, Cadranel JF, Darchy B, Barbare JC, Cazier A, Pras V, et al. Hepatotoxicity caused by therapeutic doses of paracetamol in alcoholics: report of 2 cases of fatal hepatitis in cirrhosis. Ann Med Interne (Paris) 1999;150:507-511
  469. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007;27:1219-1230 https://doi.org/10.1592/phco.27.9.1219
  470. Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients: a multicenter randomized study. BMC Med 2007;5:13 https://doi.org/10.1186/1741-7015-5-13
  471. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007;26:283-290 https://doi.org/10.1111/j.1365-2036.2007.03368.x
  472. Khalid SK, Lane J, Navarro V, Garcia-Tsao G. Use of overthe-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol 2009;7:994-999 https://doi.org/10.1016/j.cgh.2009.04.015
  473. Villeneuve JP, Raymond G, Bruneau J, Colpron L, Pomier-Layrargues G. Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects. Gastroenterol Clin Biol 1983;7:898-902
  474. Hirschfield GM, Kumagi T, Heathcote EJ. Preventative hepatology: minimising symptoms and optimising care. Liver Int 2008;28:922-934 https://doi.org/10.1111/j.1478-3231.2008.01816.x
  475. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005;12:133-141 https://doi.org/10.1097/01.mjt.0000140216.40700.95
  476. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 2010;85:451-458 https://doi.org/10.4065/mcp.2009.0534
  477. Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 1984;27:291-296 https://doi.org/10.1007/BF00542162
  478. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol 2010;16:5651-5661 https://doi.org/10.3748/wjg.v16.i45.5651
  479. Riley TR 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998;93:1563-1565 https://doi.org/10.1111/j.1572-0241.1998.00484.x
  480. Ackerman Z, Cominelli F, Reynolds TB. Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study. Am J Gastroenterol 2002;97:2033-2039 https://doi.org/10.1111/j.1572-0241.2002.05847.x
  481. Castro-Fernandez M, Sanchez-Munoz D, Galan-Jurado MV, Larraona JL, Suarez E, Lamas E, et al. Influence of nonsteroidal antiinflammatory drugs in gastrointestinal bleeding due to gastroduodenal ulcers or erosions in patients with liver cirrhosis. Gastroenterol Hepatol 2006;29:11-14
  482. Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS. Nonsteroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int 2012;32:859-866 https://doi.org/10.1111/j.1478-3231.2011.02739.x
  483. Smith HS. Opioid metabolism. Mayo Clin Proc 2009;84:613-624 https://doi.org/10.1016/S0025-6196(11)60750-7
  484. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990;29:289-297 https://doi.org/10.1111/j.1365-2125.1990.tb03638.x
  485. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999;37:17-40 https://doi.org/10.2165/00003088-199937010-00002
  486. Kotb HI, El-Kady SA, Emara SE, Fouad EA, El-Kabsh MY. Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. Br J Anaesth 2005;94:95-99 https://doi.org/10.1093/bja/aei007
  487. Kotb HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM. Pharmacokinetics of oral tramadol in patients with liver cancer. J Opioid Manag 2008;4:99-104
  488. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997;61:655-661 https://doi.org/10.1016/S0009-9236(97)90100-4
  489. Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc 2001;44:83-84
  490. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982;54:1267-1270 https://doi.org/10.1093/bja/54.12.1267
  491. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  492. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 https://doi.org/10.1093/jnci/92.3.205
  493. Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2009;45:248-260 https://doi.org/10.1016/j.ejca.2008.10.027
  494. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 https://doi.org/10.1016/j.ejca.2008.10.026
  495. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-623 https://doi.org/10.1002/cncr.24050
  496. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430 https://doi.org/10.1016/S0168-8278(01)00130-1
  497. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711 https://doi.org/10.1093/jnci/djn134
  498. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60 https://doi.org/10.1055/s-0030-1247132
  499. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-1624 https://doi.org/10.1016/0016-5085(94)90419-7
  500. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991;14:802-805 https://doi.org/10.1002/hep.1840140510
  501. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222 https://doi.org/10.1097/00000658-199902000-00009
  502. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775 https://doi.org/10.1016/0016-5085(95)90450-6
  503. Kim BK, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008;28:393-401
  504. Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002;94:2663-2668 https://doi.org/10.1002/cncr.10557
  505. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008;103:1663-1673 https://doi.org/10.1111/j.1572-0241.2008.01872.x
  506. Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Kuroki T, Minamitani S, et al. Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis. Jpn J Cancer Res 1998;89:419-426 https://doi.org/10.1111/j.1349-7006.1998.tb00580.x
  507. Kubo S, Yamamoto T, Ikebe T, Shuto T, Hirohashi K, Tanaka H, et al. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn J Cancer Res 1999;90:1076-1080 https://doi.org/10.1111/j.1349-7006.1999.tb00680.x
  508. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-459 https://doi.org/10.1097/01.sla.0000137129.98894.42
  509. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918 https://doi.org/10.1002/lt.20140
  510. Lohe F, Angele MK, Gerbes AL, Lohrs U, Jauch KW, Schauer RJ. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005;31:994-999 https://doi.org/10.1016/j.ejso.2005.06.003
  511. Park MS, Lee KW, Suh SW, You T, Choi Y, Kim H, et al. Livingdonor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation 2014;97:71-77 https://doi.org/10.1097/TP.0b013e3182a68953
  512. Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma https://doi.org/10.1016/j.jhep.2013.03.009
  513. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013;58:724-729 https://doi.org/10.1016/j.jhep.2012.11.009
  514. Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000;32:269-278 https://doi.org/10.1016/S0168-8278(00)80072-0
  515. Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011;53:136-147 https://doi.org/10.1002/hep.23965
  516. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology 2012;56:614-621 https://doi.org/10.1002/hep.25680
  517. Kim BH, Park JW, Nam BH, Kwak HW, Kim WR. Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. Liver Int 2014;34:e317-e323 https://doi.org/10.1111/liv.12519

Cited by

  1. A comparison of the risk factors of intrahepatic recurrence, early recurrencen, and multiple recurrences after resection for single nodular hepatocellular carcinoma vol.19, pp.3, 2015, https://doi.org/10.14701/kjhbps.2015.19.3.89
  2. Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma vol.19, pp.4, 2015, https://doi.org/10.14701/kjhbps.2015.19.4.167
  3. Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues vol.17, pp.1, 2016, https://doi.org/10.3348/kjr.2016.17.1.7
  4. Triple Arterial Phase MR Imaging with Gadoxetic Acid Using a Combination of Contrast Enhanced Time Robust Angiography, Keyhole, and Viewsharing Techniques and Two-Dimensional Parallel Imaging in Compa vol.17, pp.4, 2015, https://doi.org/10.3348/kjr.2016.17.4.522
  5. Angled Cool-Tip Electrode for Radiofrequency Ablation of Small Superficial Subcapsular Tumors in the Liver: A Feasibility Study vol.17, pp.5, 2015, https://doi.org/10.3348/kjr.2016.17.5.742
  6. Optimized Performance of FlightPlan during Chemoembolization for Hepatocellular Carcinoma: Importance of the Proportion of Segmented Tumor Area vol.17, pp.5, 2015, https://doi.org/10.3348/kjr.2016.17.5.771
  7. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines vol.34, pp.3, 2015, https://doi.org/10.3857/roj.2016.01970
  8. Risk factors of postoperative ascites on hepatic resection for hepatocellular carcinoma vol.20, pp.4, 2015, https://doi.org/10.14701/ahbps.2016.20.4.153
  9. Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma vol.19, pp.3, 2017, https://doi.org/10.3233/cbm-160357
  10. New Radiofrequency Device to Reduce Bleeding after Core Needle Biopsy: Experimental Study in a Porcine Liver Model vol.18, pp.1, 2015, https://doi.org/10.3348/kjr.2017.18.1.173
  11. Methodology for Developing Evidence-Based Clinical Imaging Guidelines: Joint Recommendations by Korean Society of Radiology and National Evidence-Based Healthcare Collaborating Agency vol.18, pp.1, 2015, https://doi.org/10.3348/kjr.2017.18.1.208
  12. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology vol.18, pp.3, 2015, https://doi.org/10.3348/kjr.2017.18.3.427
  13. Quantitative Measurement of Hepatic Fibrosis with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Patients with Chronic Hepatitis B Infection: A Comparative Study on Aspartate Aminotransferase t vol.18, pp.3, 2017, https://doi.org/10.3348/kjr.2017.18.3.444
  14. T2 * Mapping from Multi-Echo Dixon Sequence on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment? vol.18, pp.4, 2015, https://doi.org/10.3348/kjr.2017.18.4.682
  15. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017 vol.11, pp.4, 2015, https://doi.org/10.5582/bst.2017.01202
  16. 간동맥 화학색전술을 받은 간암환자의 영양상태에 미치는 영향요인 vol.11, pp.1, 2015, https://doi.org/10.12811/kshsm.2017.11.1.159
  17. Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma vol.104, pp.11, 2015, https://doi.org/10.1002/bjs.10597
  18. Prognostic factors after curative resection hepatocellular carcinoma and the surgeon's role vol.93, pp.5, 2015, https://doi.org/10.4174/astr.2017.93.5.252
  19. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis vol.43, pp.1, 2018, https://doi.org/10.1007/s00261-017-1209-1
  20. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma vol.43, pp.1, 2015, https://doi.org/10.1007/s00261-017-1317-y
  21. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor t vol.82, pp.3, 2015, https://doi.org/10.1007/s00280-018-3638-0
  22. A systematic review of publications on charged particle therapy for hepatocellular carcinoma vol.23, pp.3, 2015, https://doi.org/10.1007/s10147-017-1190-2
  23. The impact of perioperative allogeneic blood transfusion on prognosis of hepatocellular carcinoma after radical hepatectomy : A systematic review and meta-analysis of cohort studies vol.97, pp.43, 2015, https://doi.org/10.1097/md.0000000000012911
  24. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review vol.286, pp.1, 2018, https://doi.org/10.1148/radiol.2017170554
  25. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients vol.289, pp.3, 2015, https://doi.org/10.1148/radiol.2018181494
  26. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma vol.9, pp.3, 2015, https://doi.org/10.18632/oncotarget.23428
  27. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials vol.11, pp.None, 2015, https://doi.org/10.2147/ott.s164651
  28. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis vol.210, pp.2, 2015, https://doi.org/10.2214/ajr.17.18300
  29. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B vol.12, pp.2, 2015, https://doi.org/10.5009/gnl17092
  30. Current topics in the surgical treatments for hepatocellular carcinoma vol.2, pp.2, 2015, https://doi.org/10.1002/ags3.12065
  31. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma vol.36, pp.1, 2015, https://doi.org/10.3857/roj.2017.00409
  32. Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma? vol.36, pp.2, 2018, https://doi.org/10.3857/roj.2017.00598
  33. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy vol.10, pp.9, 2015, https://doi.org/10.4254/wjh.v10.i9.571
  34. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy vol.129, pp.1, 2018, https://doi.org/10.1016/j.radonc.2017.11.027
  35. Detection of recurrent hepatocellular carcinoma after surgical resection: Non-contrast liver MR imaging with diffusion-weighted imaging versus gadoxetic acid-enhanced MR imaging vol.91, pp.1090, 2015, https://doi.org/10.1259/bjr.20180177
  36. Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer vol.194, pp.11, 2018, https://doi.org/10.1007/s00066-018-1342-y
  37. Polymorphisms in the 3′-UTR of SCD5 gene are associated with hepatocellular carcinoma in Korean population vol.45, pp.6, 2018, https://doi.org/10.1007/s11033-018-4313-6
  38. Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma vol.9, pp.None, 2015, https://doi.org/10.1038/s41598-019-47365-4
  39. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma vol.7, pp.2, 2019, https://doi.org/10.14218/jcth.2018.00060
  40. Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study vol.20, pp.12, 2015, https://doi.org/10.3348/kjr.2019.0363
  41. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
  42. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma vol.58, pp.1, 2015, https://doi.org/10.1002/mc.22908
  43. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients vol.11, pp.None, 2015, https://doi.org/10.1177/1758835919866072
  44. Added Value of sequentially performed gadoxetic acid‐enhanced liver MRI for the diagnosis of small (10–19 mm) or atypical hepatic observations at contrast‐enhanced CT: A prospective vol.49, pp.2, 2015, https://doi.org/10.1002/jmri.26199
  45. Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation vol.29, pp.2, 2015, https://doi.org/10.1007/s00330-018-5557-1
  46. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications vol.29, pp.2, 2015, https://doi.org/10.1007/s00330-018-5617-6
  47. Paeonol-mediated apoptosis of hepatocellular carcinoma cells by NF-κB pathway vol.17, pp.2, 2015, https://doi.org/10.3892/ol.2018.9730
  48. Conventional Chemoembolization for Hepatocellular Carcinoma: Role of Cone-Beam Computed Tomography Guidance vol.19, pp.1, 2019, https://doi.org/10.17998/jlc.19.1.19
  49. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B vol.25, pp.1, 2015, https://doi.org/10.3350/cmh.2018.0040
  50. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout wi vol.29, pp.4, 2019, https://doi.org/10.1007/s00330-018-5727-1
  51. Brachytherapy using elastin-like polypeptide with different concentrations of 131I for treatment of VX2 liver tumor in rabbits vol.27, pp.8, 2015, https://doi.org/10.11569/wcjd.v27.i8.485
  52. Questionable correlation of the apparent diffusion coefficient with the histological grade and microvascular invasion in small hepatocellular carcinoma vol.74, pp.5, 2019, https://doi.org/10.1016/j.crad.2019.01.019
  53. 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma vol.13, pp.3, 2015, https://doi.org/10.5009/gnl19024
  54. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines vol.20, pp.6, 2015, https://doi.org/10.3348/kjr.2018.0450
  55. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma vol.20, pp.7, 2015, https://doi.org/10.3348/kjr.2019.0140
  56. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma vol.292, pp.2, 2019, https://doi.org/10.1148/radiol.2019190035
  57. Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018 vol.25, pp.32, 2019, https://doi.org/10.3748/wjg.v25.i32.4749
  58. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS vol.44, pp.9, 2019, https://doi.org/10.1007/s00261-019-02077-1
  59. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma vol.8, pp.16, 2015, https://doi.org/10.1002/cam4.2570
  60. Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta‐analyses vol.63, pp.6, 2019, https://doi.org/10.1111/1754-9485.12948
  61. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma vol.19, pp.1, 2015, https://doi.org/10.1186/s12885-019-6040-3
  62. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging vol.30, pp.1, 2020, https://doi.org/10.1007/s00330-019-06369-4
  63. Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma vol.37, pp.1, 2015, https://doi.org/10.1080/02656736.2020.1849824
  64. Performance Evaluation and Clinical Usefulness of α-fetoprotein Test Measured on Sysmex HISCL-5000 vol.10, pp.1, 2020, https://doi.org/10.3343/lmo.2020.10.1.33
  65. Comparative Analysis of Image Quality and Adverse Events between Iopamidol 250 and Ioversol 320 in Hepatic Angiography for Transcatheter Arterial Chemoembolization vol.81, pp.1, 2015, https://doi.org/10.3348/jksr.2020.81.1.166
  66. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review vol.145, pp.None, 2015, https://doi.org/10.1016/j.radonc.2019.12.004
  67. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features vol.30, pp.5, 2015, https://doi.org/10.1007/s00330-019-06623-9
  68. Hepatocellular carcinoma and multiple myeloma with elevated globulin: a case report and literature review vol.48, pp.5, 2015, https://doi.org/10.1177/0300060520920395
  69. Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma vol.12, pp.5, 2015, https://doi.org/10.3390/cancers12051300
  70. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy vol.71, pp.3, 2015, https://doi.org/10.1093/cid/ciz860
  71. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma vol.26, pp.4, 2020, https://doi.org/10.3350/cmh.2020.0005
  72. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance vol.40, pp.7, 2015, https://doi.org/10.1148/rg.2020200104
  73. Percutaneous Argon-Helium Cryoablation for Small Hepatocellular Carcinoma Located Adjacent to a Major Organ or Viscus: A Retrospective Study of 92 Patients at a Single Center vol.27, pp.None, 2015, https://doi.org/10.12659/msm.931473
  74. No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study vol.22, pp.None, 2021, https://doi.org/10.3348/kjr.2021.0319
  75. Varices on computed tomography as predictor of survival after hepatic resection in patients with single hepatocellular carcinoma vol.36, pp.1, 2015, https://doi.org/10.1111/jgh.15117
  76. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Sc vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/6670367
  77. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta‐analysis vol.36, pp.2, 2015, https://doi.org/10.1111/jgh.15180
  78. Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report vol.49, pp.2, 2015, https://doi.org/10.1177/0300060521994406
  79. Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease vol.13, pp.4, 2015, https://doi.org/10.3390/cancers13040790
  80. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea vol.39, pp.1, 2021, https://doi.org/10.1007/s10637-020-00977-4
  81. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? vol.97, pp.2, 2015, https://doi.org/10.1080/09553002.2021.1857453
  82. Exosomal miR-125b Exerts Anti-Metastatic Properties and Predicts Early Metastasis of Hepatocellular Carcinoma vol.11, pp.None, 2021, https://doi.org/10.3389/fonc.2021.637247
  83. Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118) vol.40, pp.2, 2015, https://doi.org/10.14366/usg.20052
  84. Current epidemiology in hepatocellular carcinoma vol.15, pp.11, 2021, https://doi.org/10.1080/17474124.2021.1991792
  85. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients vol.15, pp.6, 2021, https://doi.org/10.1007/s12072-021-10262-y